Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Kumai, Takumi ^a   Oikawa, Kensuke ^a   Aoki, Naoko ^a   Kimura, Shoji ^a   Harabuchi, Yasuaki ^a   Celis, Esteban ^b   Kobayashi, Hiroya ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

COX 2; EGFR; HNSCC; TGF

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYCLOOXYGENASE 2 INHIBITOR; ERLOTINIB; HLA DR ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E2; PROTEIN ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GINGIVA TUMOR; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOREGULATION; MOLECULAR RECOGNITION; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; TUMOR IMMUNITY; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CD4+ T LYMPHOCYTE; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DINOPROSTONE; ERLOTINIB HYDROCHLORIDE; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

EID: 84910082485     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0265-3     Document Type: Article

References (32)

1. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998, 4:328-332. 10.1038/nm0398-328, 9500607.
2. van den Boorn JG, Hartmann G. Turning tumors into vaccines: co-opting the innate immune system. Immunity 2013, 39:27-37. 10.1016/j.immuni.2013.07.011, 23890061.
3. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013, 73:1128-1141. 10.1158/0008-5472.CAN-12-2731, 23221383.
4. Izhak L, Ambrosino E, Kato S, Parish ST, O'Konek JJ, Weber H, Xia Z, Venzon D, Berzofsky JA, Terabe M. Delicate balance among three types of T cells in concurrent regulation of tumor immunity. Cancer Res 2013, 73:1514-1523. 10.1158/0008-5472.CAN-12-2567, 23319803.
5. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013, 19:462-468. 10.1158/1078-0432.CCR-12-2625, 23169436.
6. Kobayashi H, Kumai T, Hayashi S, Matsuda Y, Aoki N, Sato K, Kimura S, Celis E. A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope. Cancer Immunol Immunother 2012, 61:2215-2225. 10.1007/s00262-012-1284-7, 22638550.
7. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, der Meer DM B-V, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847. 10.1056/NEJMoa0810097, 19890126.
8. Kumai T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy. Br J Cancer 2013, 109:2155-2166. 10.1038/bjc.2013.577, 24045666.
9. Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res 2011, 17:4400-4413. 10.1158/1078-0432.CCR-10-3283, 21586626.
10. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956. 10.1038/onc.2008.19, 18297114.
11. Weppler SA, Li Y, Dubois L, Lieuwes N, Jutten B, Lambin P, Wouters BG, Lammering G. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother Oncol 2007, 83:333-339. 10.1016/j.radonc.2007.04.025, 17512071.
12. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, Kenner L, Sordella R. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 2010, 107:15535-15540. 10.1073/pnas.1009472107, 20713723.
13. Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 2000, 60:5228-5236. 11016652.
14. Cecil DL, Holt GE, Park KH, Gad E, Rastetter L, Childs J, Higgins D, Disis ML. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. Cancer Res 2014, 74:2710-2718. 10.1158/0008-5472.CAN-13-3286, 24778415.
15. Tsan MF, Gao B. Heat shock proteins and immune system. J Leukoc Biol 2009, 85:905-910. 10.1189/jlb.0109005, 19276179.
16. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002, 99:12293-12297. 10.1073/pnas.192461099, 12218188.
17. Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production: role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol 1994, 153:1674-1686. 8046239.
18. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005, 65:5211-5220. 10.1158/0008-5472.CAN-05-0141, 15958566.
19. Yang L, Amann JM, Kikuchi T, Porta R, Guix M, Gonzalez A, Park KH, Billheimer D, Arteaga CL, Tai HH, DuBois R, Carbone DP, Johnson DH. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res 2007, 67:5587-5593. 10.1158/0008-5472.CAN-06-2287, 17575121.
20. Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K: Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 2014, epub ahead of print..
21. Grovdal LM, Kim J, Holst MR, Knudsen SL, Grandal MV, van Deurs B. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cell Signal 2012, 24:296-301. 10.1016/j.cellsig.2011.09.012, 21951604.
22. Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K, Brait M, Hoque M, Ling S, Bedi A, Sidransky D. The TGFbeta-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 2014, 74:3995-4005. 10.1158/0008-5472.CAN-14-0110, 24830724.
23. Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Kim CH, Lee JC. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 2009, 63:219-226. 10.1016/j.lungcan.2008.05.017, 18599154.
24. Fletcher EV, Love-Homan L, Sobhakumari A, Feddersen CR, Koch AT, Goel A, Simons AL. EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC. Mol Cancer Res 2013, 11:1574-1584. 10.1158/1541-7786.MCR-13-0187, 24048704.
25. Serizawa M, Takahashi T, Yamamoto N, Koh Y. Combined treatment with erlotinib and a transforming growth factor-beta type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. J Thorac Oncol 2013, 8:259-269. 23334091.
26. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756-2761. 10.4049/jimmunol.169.5.2756, 12193750.
27. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J 2004, 23:1155-1165. 10.1038/sj.emboj.7600069, 14976548.
28. Costea DE, Hills A, Osman AH, Thurlow J, Kalna G, Huang X, Pena Murillo C, Parajuli H, Suliman S, Kulasekara KK, Johannessen AC, Partridge M. Identification of two distinct carcinoma-associated fibroblast subtypes with differential tumor-promoting abilities in oral squamous cell carcinoma. Cancer Res 2013, 73:3888-3901. 10.1158/0008-5472.CAN-12-4150, 23598279.
29. Schrey MP, Patel KV. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts: regulation by inflammatory mediators. Br J Cancer 1995, 72:1412-1419. 10.1038/bjc.1995.523, 8519653.
30. Mao Y, Poschke I, Wennerberg E, Pico de Coana Y, Egyhazi Brage S, Schultz I, Hansson J, Masucci G, Lundqvist A, Kiessling R. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 2013, 73:3877-3887. 10.1158/0008-5472.CAN-12-4115, 23633486.
31. Ahmadi N, Goldman R, Seillier-Moiseiwitsch F, Noone AM, Kosti O, Davidson BJ. Decreased risk of squamous cell carcinoma of the head and neck in users of nonsteroidal anti-inflammatory drugs. Int J Otolaryngol 2010, 2010:424161. 10.1155/2010/424161, 20628564.
32. Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, Wirth L, Nikiforova MN, Siegfried JM, Grandis JR. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res 2014, 20:3289-3298. 10.1158/1078-0432.CCR-13-3360, 24727329.